title: [Results of cyclosporin treatment of severe, chronic psoriasis vulgaris].
abstract: Controlled double-blind studies have demonstrated the efficacy of 14 mg/kg per day cyclosporin A (CsA) in patients with severe psoriasis. Recently a placebo-controlled double-blind randomized study confirmed that CsA therapy (mean dose 5.5 mg/kg/day improves psoriasis significantly. We have carried out a placebo-controlled, double-blind, randomized trial involving 12 patients suffering from severe psoriasis resistant to local therapy. Within 4 weeks, 5 mg/kg per day CsA resulted in 6 patients in a mean reduction of 72.5% of the PASI score, which differed significantly from the mean reduction of 18.1% in 6 patients receiving placebo. The most important side-effect was reversible hypertension in 1 patient. The preliminary results of a dose-finding study that started recently indicate that 1-3 mg/kg per day CsA results in a significant improvement in the patient's condition.
authors.affiliation: Dermatologische Klinik und Poliklinik, Technischen Universität München.
authors.forename: R
authors.initials: R
authors.lastname: Engst
authors.forename: J
authors.initials: J
authors.lastname: Huber
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D003524:Cyclosporins
vernacular_title: Ergebnisse einer Cyclosporin-Behandlung bei schwerer, chronischer Psoriasis vulgaris.